Cytomegalovirus pneumonia in hematopoietic stem cell recipients

Journal of Intensive Care Medicine

Volumn 29, Issue 4, 2014, Pages 200-212

  Travi, Giovanna ^a   Pergam, Steven A ^b,c  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

antiviral; CMV pneumonia; cytomegalovirus; hematopoietic cell transplant; prevention

Indexed keywords

ANTIVIRUS AGENT; CYTOMEGALOVIRUS VACCINE; IMMUNOGLOBULIN;

ADOPTIVE IMMUNOTHERAPY; ANTIVIRAL THERAPY; BLOOD ANALYSIS; BRONCHOSCOPY; CONDITIONING; CYTOMEGALOVIRUS INFECTION; CYTOMEGALOVIRUS PNEUMONIA; CYTOPATHOLOGY; DIFFERENTIAL DIAGNOSIS; DONOR; GRAFT RECIPIENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOPATHOLOGY; IMMUNOPROPHYLAXIS; LUNG BIOPSY; LUNG LAVAGE; NON INVASIVE PROCEDURE; PATHOGENESIS; PATHOPHYSIOLOGY; PHYSICAL DISEASE BY BODY FUNCTION; PNEUMONIA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RADIOLOGY; REVIEW; RISK FACTOR; VIRUS DETECTION; ADVERSE EFFECTS; CYTOMEGALOVIRUS INFECTIONS; PNEUMONIA, VIRAL;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; PNEUMONIA, VIRAL; RISK FACTORS;

EID: 84905030074     PISSN: 08850666     EISSN: 15251489     Source Type: Journal    
DOI: 10.1177/0885066613476454     Document Type: Review

References (160)

1. Konoplev S, Champlin RE, Giralt S, et al. Cytomegalovirus pneumonia in adult autologous blood and marrow transplant recipients. Bone Marrow Transplant. 2001 ; 27 (8). 877-881 (Pubitemid 32496423)
2. Ljungman P. CMV infections after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2008 ; 42 (suppl 1). S70 - S72
3. Boeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant. 2003 ; 9 (9). 543-558 (Pubitemid 38351787)
4. Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010 ; 363 (22). 2091-2101
5. Green ML, Leisenring W, Stachel D, et al. Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012 ; 18 (11). 1687-1699
6. Milano F, Pergam SA, Xie H, et al. Intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipients. Blood. 2011 ; 118 (20). 5689-5696
7. Ison MG, Fishman JA. Cytomegalovirus pneumonia in transplant recipients. Clin Chest Med. 2005 ; 26 (4). 691-705 (Pubitemid 41563267)
8. Kotloff RM, Ahya VN, Crawford SW. Pulmonary complications of solid organ and hematopoietic stem cell transplantation. Am J Respir Crit Care Med. 2004 ; 170 (1). 22-48 (Pubitemid 38997749)
9. Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood. 2009 ; 113 (23). 5711-5719
10. Boeckh M, Leisenring W, Riddell SR, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood. 2003 ; 101 (2). 407-414 (Pubitemid 36077556)
11. Hakki M, Riddell SR, Storek J, et al. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. Blood. 2003 ; 102 (8). 3060-3067 (Pubitemid 37248884)
12. Ozdemir E, Saliba RM, Champlin RE, et al. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant. 2007 ; 40 (2). 125-136 (Pubitemid 47046210)
13. Ljungman P. Cytomegalovirus pneumonia: presentation, diagnosis, and treatment. Semin Respir Infect. 1995 ; 10 (4). 209-215 (Pubitemid 26007452)
14. Junghanss C, Storb R, Maris MB, et al. Impact of unrelated donor status on the incidence and outcome of cytomegalovirus infections after non-myeloablative allogeneic stem cell transplantation. Br J Haematol. 2003 ; 123 (4). 662-670 (Pubitemid 37468063)
15. van Burik JA, Carter SL, Freifeld AG, et al. Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease. Biol Blood Marrow Transplant. 2007 ; 13 (12). 1487-1498 (Pubitemid 350091387)
16. Alexander BT, Hladnik LM, Augustin KM, et al. Use of cytomegalovirus intravenous immune globulin for the adjunctive treatment of cytomegalovirus in hematopoietic stem cell transplant recipients. Pharmacotherapy. 2010 ; 30 (6). 554-561
17. George B, Pati N, Gilroy N, et al. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy. Transpl Infect Dis. 2010 ; 12 (4). 322-329
18. Buyck HC, Prentice HG, Griffiths PD, Emery VC. The risk of early and late CMV DNAemia associated with Campath use in stem cell transplant recipients. Bone Marrow Transplant. 2010 ; 45 (7). 1212-1219
19. Tomonari A, Takahashi S, Ooi J, et al. Impact of cytomegalovirus serostatus on outcome of unrelated cord blood transplantation for adults: a single-institute experience in Japan. Eur J Haematol. 2008 ; 80 (3). 251-257 (Pubitemid 351253457)
20. Pergam SA, Xie H, Sandhu R, et al. Efficiency and risk factors for CMV transmission in seronegative hematopoietic stem cell recipients. Biol Blood Marrow Transplant. 2012 ; 18 (9). 1391-1400
21. Kollman C, Howe CW, Anasetti C, et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood. 2001 ; 98 (7). 2043-2051
22. Ljungman P, Brand R, Einsele H, Frassoni F, Niederwieser D, Cordonnier C. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood. 2003 ; 102 (13). 4255-4260 (Pubitemid 37494081)
23. Boeckh M, Nichols WG. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood. 2004 ; 103 (6). 2003-2008 (Pubitemid 38326213)
24. Nichols WG, Corey L, Gooley T, Davis C, Boeckh M. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis. 2002 ; 185 (3). 273-282 (Pubitemid 34107239)
25. Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Infect Dis Clin North Am. 2010 ; 24 (2). 319-337
26. Trenschel R, Ross S, Husing J, et al. Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT. Bone Marrow Transplant. 2000 ; 25 (6). 665-672 (Pubitemid 30156593)
27. Brunstein CG, Barker JN, Weisdorf DJ, et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood. 2007 ; 110 (8). 3064-3070 (Pubitemid 350006962)
28. Cornetta K, Laughlin M, Carter S, et al. Umbilical cord blood transplantation in adults: results of the prospective cord blood transplantation (COBLT). Biol Blood Marrow Transplant. 2005 ; 11 (2). 149-160 (Pubitemid 40186212)
29. Baron F, Storer B, Maris MB, et al. Unrelated donor status and high donor age independently affect immunologic recovery after nonmyeloablative conditioning. Biol Blood Marrow Transplant. 2006 ; 12 (11). 1176-1187 (Pubitemid 44660855)
30. Pinana JL, Martino R, Barba P, et al. Cytomegalovirus infection and disease after reduced intensity conditioning allogeneic stem cell transplantation: single-centre experience. Bone Marrow Transplant. 2010 ; 45 (3). 534-542
31. Nakamae H, Kirby KA, Sandmaier BM, et al. Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2009 ; 15 (6). 694-703
32. Takenaka K, Gondo H, Tanimoto K, et al. Increased incidence of cytomegalovirus (CMV) infection and CMV-associated disease after allogeneic bone marrow transplantation from unrelated donors. The Fukuoka bone marrow transplantation group. Bone Marrow Transplant. 1997 ; 19 (3). 241-248 (Pubitemid 27077480)
33. Dodero A, Carrabba M, Milani R, et al. Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed. Exp Hematol. 2005 ; 33 (8). 920-927 (Pubitemid 40982659)
34. Holmberg LA, Boeckh M, Hooper H, et al. Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood. 1999 ; 94 (12). 4029-4035
35. Orlandi EM, Baldanti F, Citro A, Pochintesta L, Gatti M, Lazzarino M. Monitoring for cytomegalovirus and Epstein-Barr virus infection in chronic lymphocytic leukemia patients receiving i.v. fludarabine-cyclophosphamide combination and alemtuzumab as consolidation therapy. Haematologica. 2008 ; 93 (11). 1758-1760
36. Schmidt-Hieber M, Schwarck S, Stroux A, et al. Immune reconstitution and cytomegalovirus infection after allogeneic stem cell transplantation: the important impact of in vivo T cell depletion. Int J Hematol. 2010 ; 91 (5). 877-885
37. Schaenman JM, Shashidhar S, Rhee C, et al. Early CMV viremia is associated with impaired viral control following nonmyeloablative hematopoietic cell transplantation with a total lymphoid irradiation and antithymocyte globulin preparative regimen. Biol Blood Marrow Transplant. 2011 ; 17 (5). 693-702
38. Yoon HS, Lee JH, Choi ES, et al. Cytomegalovirus infection in children who underwent hematopoietic stem cell transplantation at a single center: a retrospective study of the risk factors. Pediatr Transplant. 2009 ; 13 (7). 898-905
39. Asano-Mori Y, Kanda Y, Oshima K, et al. Clinical features of late cytomegalovirus infection after hematopoietic stem cell transplantation. Int J Hematol. 2008 ; 87 (3). 310-318
40. George B, Kerridge IH, Gilroy N, et al. A risk score for early cytomegalovirus reactivation after allogeneic stem cell transplantation identifies low-, intermediate-, and high-risk groups: reactivation risk is increased by graft-versus-host disease only in the intermediate-risk group. Transpl Infect Dis. 2012 ; 14 (2). 141-148
41. Olkinuora H, von Willebrand E, Kantele JM, et al. The impact of early viral infections and graft-versus-host disease on immune reconstitution following paediatric stem cell transplantation. Scand J Immunol. 2011 ; 73 (6). 586-593
42. Miller W, Flynn P, McCullough J, et al. Cytomegalovirus infection after bone marrow transplantation: an association with acute graft-v-host disease. Blood. 1986 ; 67 (4). 1162-1167 (Pubitemid 16116435)
43. Osarogiagbon RU, Defor TE, Weisdorf MA, Erice A, Weisdorf DJ. CMV antigenemia following bone marrow transplantation: risk factors and outcomes. Biol Blood Marrow Transplant. 2000 ; 6 (3). 280-288
44. Ljungman P, Perez-Bercoff L, Jonsson J, et al. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica. 2006 ; 91 (1). 78-83 (Pubitemid 43235389)
45. Onishi C, Ohashi K, Sawada T, et al. A high risk of life-threatening infectious complications in mycophenolate mofetil treatment for acute or chronic graft-versus-host disease. Int J Hematol. 2010 ; 91 (3). 464-470
46. Kasper C, Sayer HG, Mugge LO, et al. Combined standard graft-versus-host disease (GvHD) prophylaxis with mycophenolate mofetil (MMF) in allogeneic peripheral blood stem cell transplantation from unrelated donors. Bone Marrow Transplant. 2004 ; 33 (1). 65-69 (Pubitemid 38159706)
47. Hambach L, Stadler M, Dammann E, Ganser A, Hertenstein B. Increased risk of complicated CMV infection with the use of mycophenolate mofetil in allogeneic stem cell transplantation. Bone Marrow Transplant. 2002 ; 29 (11). 903-906 (Pubitemid 34814698)
48. Marty FM, Bryar J, Browne SK, et al. Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. Blood. 2007 ; 110 (2). 490-500 (Pubitemid 47105386)
49. Ruell J, Barnes C, Mutton K, et al. Active CMV disease does not always correlate with viral load detection. Bone Marrow Transplant. 2007 ; 40 (1). 55-61 (Pubitemid 47018414)
50. Jang JE, Hyun SY, Kim YD, et al. Risk factors for progression from cytomegalovirus viremia to cytomegalovirus disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012 ; 18 (6). 881-886
51. Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Griffiths PD. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet. 2000 ; 355 (9220). 2032-2036 (Pubitemid 30339241)
52. Soderberg-Naucler C. Human cytomegalovirus persists in its host and attacks and avoids elimination by the immune system. Crit Rev Immunol. 2006 ; 26 (3). 231-264
53. Champlin RE, Schmitz N, Horowitz MM, et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR histocompatibility and stem cell sources working committee and the European group for blood and marrow transplantation (EBMT). Blood. 2000 ; 95 (12). 3702-3709
54. Hahn G, Jores R, Mocarski ES. Cytomegalovirus remains latent in a common precursor of dendritic and myeloid cells. Proc Natl Acad Sci U S A. 1998 ; 95 (7). 3937-3942 (Pubitemid 28173232)
55. Kondo K, Kaneshima H, Mocarski ES. Human cytomegalovirus latent infection of granulocyte-macrophage progenitors. Proc Natl Acad Sci U S A. 1994 ; 91 (25). 11879-11883 (Pubitemid 24368567)
56. Kondo K, Mocarski ES. Cytomegalovirus latency and latency-specific transcription in hematopoietic progenitors. Scand J Infect Dis Suppl. 1995 ; 99: 63-67 (Pubitemid 26075332)
57. Kondo K, Xu J, Mocarski ES. Human cytomegalovirus latent gene expression in granulocyte-macrophage progenitors in culture and in seropositive individuals. Proc Natl Acad Sci U S A. 1996 ; 93 (20). 11137-11142 (Pubitemid 26333131)
58. Taylor-Wiedeman J, Sissons JG, Borysiewicz LK, Sinclair JH. Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells. J Gen Virol. 1991 ; 72 (pt 9). 2059-2064
59. Koffron AJ, Hummel M, Patterson BK, et al. Cellular localization of latent murine cytomegalovirus. J Virol. 1998 ; 72 (1). 95-103 (Pubitemid 28048817)
60. Kurz SK, Rapp M, Steffens HP, Grzimek NK, Schmalz S, Reddehase MJ. Focal transcriptional activity of murine cytomegalovirus during latency in the lungs. J Virol. 1999 ; 73 (1). 482-494 (Pubitemid 28565393)
61. Toorkey CB, Carrigan DR. Immunohistochemical detection of an immediate early antigen of human cytomegalovirus in normal tissues. J Infect Dis. 1989 ; 160 (5). 741-751 (Pubitemid 19266827)
62. Soderberg-Naucler C, Fish KN, Nelson JA. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell. 1997 ; 91 (1). 119-126 (Pubitemid 27431318)
63. de Maar EF, Verschuuren EA, Harmsen MC, The TH, van Son WJ. Pulmonary involvement during cytomegalovirus infection in immunosuppressed patients. Transpl Infect Dis. 2003 ; 5 (3). 112-120 (Pubitemid 37356353)
64. Barry SM, Johnson MA, Janossy G. Cytopathology or immunopathology? The puzzle of cytomegalovirus pneumonitis revisited. Bone Marrow Transplant. 2000 ; 26 (6). 591-597
65. Riddell SR. Pathogenesis of cytomegalovirus pneumonia in immunocompromised hosts. Semin Respir Infect. 1995 ; 10 (4). 199-208 (Pubitemid 26007451)
66. Grundy JE, Shanley JD, Griffiths PD. Is cytomegalovirus interstitial pneumonitis in transplant recipients an immunopathological condition?. Lancet. 1987 ; 2 (8566). 996-999 (Pubitemid 17150860)
67. Squire SB, Lipman MC, Bagdades EK, et al. Severe cytomegalovirus pneumonitis in HIV infected patients with higher than average CD4 counts. Thorax. 1992 ; 47 (4). 301-304
68. Shanley JD, Thrall RS, Forman SJ. Murine cytomegalovirus replication in the lungs of athymic BALB/c nude mice. J Infect Dis. 1997 ; 175 (2). 309-315 (Pubitemid 27052236)
69. Steffens HP, Kurz S, Holtappels R, Reddehase MJ. Preemptive CD8 T-cell immunotherapy of acute cytomegalovirus infection prevents lethal disease, limits the burden of latent viral genomes, and reduces the risk of virus recurrence. J Virol. 1998 ; 72 (3). 1797-1804 (Pubitemid 28100730)
70. Razonable RR. Immune-based therapies for cytomegalovirus infection. Immunotherapy. 2010 ; 2 (1). 117-130
71. Pergam S, Boeckh M, Hsu K, et al San Francisco, CA: ; September 2009 :
72. Zaia JA, Sun JY, Gallez-Hawkins GM, et al. The effect of single and combined activating killer immunoglobulin-like receptor genotypes on cytomegalovirus infection and immunity after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2009 ; 15 (3). 315-325
73. Cook M, Briggs D, Craddock C, et al. Donor KIR genotype has a major influence on the rate of cytomegalovirus reactivation following T-cell replete stem cell transplantation. Blood. 2006 ; 107 (3). 1230-1232 (Pubitemid 43156330)
74. Escudier E, Fleury J, Cordonnier C, Vernant JP, Bernaudin JF. Large granular lymphocytes in bronchoalveolar lavage fluids from immunocompromised patients with cytomegalovirus pneumonitis. Am J Clin Pathol. 1986 ; 86 (5). 641-645 (Pubitemid 17181366)
75. Biron CA, Byron KS, Sullivan JL. Severe herpesvirus infections in an adolescent without natural killer cells. N Engl J Med. 1989 ; 320 (26). 1731-1735 (Pubitemid 19163129)
76. Persoons MC, Stals FS, van dam Mieras MC, Bruggeman CA. Multiple organ involvement during experimental cytomegalovirus infection is associated with disseminated vascular pathology. J Pathol. 1998 ; 184 (1). 103-109 (Pubitemid 28086161)
77. Grefte A, Blom N, van der Giessen M, van Son W, The TH. Ultrastructural analysis of circulating cytomegalic cells in patients with active cytomegalovirus infection: evidence for virus production and endothelial origin. J Infect Dis. 1993 ; 168 (5). 1110-1118 (Pubitemid 23317123)
78. Grefte A, van der Giessen M, van Son W, The TH. Circulating cytomegalovirus (CMV)-infected endothelial cells in patients with an active CMV infection. J Infect Dis. 1993 ; 167 (2). 270-277 (Pubitemid 23036426)
79. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002 ; 34 (8). 1094-1097 (Pubitemid 34289682)
80. Crumpacker CS, Zhang JL. Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. 7 th ed. Philadelphia, PA: Churchill Livingstone; 1971-1987. Philadelphia, PA: Churchill Livingstone ; 1971-1987.
81. Franquet T, Lee KS, Muller NL. Thin-section CT findings in 32 immunocompromised patients with cytomegalovirus pneumonia who do not have AIDS. AJR Am J Roentgenol. 2003 ; 181 (4). 1059-1063 (Pubitemid 37151791)
82. Maschmeyer G. Pneumonia in febrile neutropenic patients: radiologic diagnosis. Curr Opin Oncol. 2001 ; 13 (4). 229-235 (Pubitemid 32578987)
83. Gasparetto EL, Ono SE, Escuissato D, et al. Cytomegalovirus pneumonia after bone marrow transplantation: high resolution CT findings. Br J Radiol. 2004 ; 77 (921). 724-727 (Pubitemid 39386918)
84. Kang EY, Patz EF, Muller NL. Cytomegalovirus pneumonia in transplant patients: CT findings. J Comput Assist Tomogr. 1996 ; 20 (2). 295-299 (Pubitemid 26108719)
85. Shimada A, Koga T, Shimada M, et al. Cytomegalovirus pneumonitis presenting small nodular opacities. Intern Med. 2004 ; 43 (12). 1198-1200 (Pubitemid 40074161)
86. Tamm M, Traenkle P, Grilli B, et al. Pulmonary cytomegalovirus infection in immunocompromised patients. Chest. 2001 ; 119 (3). 838-843 (Pubitemid 32197657)
87. Crawford SW, Bowden RA, Hackman RC, Gleaves CA, Meyers JD, Clark JG. Rapid detection of cytomegalovirus pulmonary infection by bronchoalveolar lavage and centrifugation culture. Ann Intern Med. 1988 ; 108 (2). 180-185 (Pubitemid 18081189)
88. Gleaves CA, Meyers JD. Rapid detection of cytomegalovirus in bronchoalveolar lavage specimens from marrow transplant patients: evaluation of a direct fluorescein-conjugated monoclonal antibody reagent. J Virol Methods. 1989 ; 26 (3). 345-349 (Pubitemid 20018136)
89. Eriksson BM, Brytting M, Zweygberg-Wirgart B, Hillerdal G, Olding-Stenkvist E, Linde A.. Diagnosis of cytomegalovirus in bronchoalveolar lavage by polymerase chain reaction, in comparison with virus isolation and detection of viral antigen. Scand J Infect Dis. 1993 ; 25 (4). 421-427 (Pubitemid 23268107)
90. Cathomas G, Morris P, Pekle K, Cunningham I, Emanuel D. Rapid diagnosis of cytomegalovirus pneumonia in marrow transplant recipients by bronchoalveolar lavage using the polymerase chain reaction, virus culture, and the direct immunostaining of alveolar cells. Blood. 1993 ; 81 (7). 1909-1914 (Pubitemid 23101608)
91. Ruutu P, Ruutu T, Volin L, Tukiainen P, Ukkonen P, Hovi T. Cytomegalovirus is frequently isolated in bronchoalveolar lavage fluid of bone marrow transplant recipients without pneumonia. Ann Intern Med. 1990 ; 112 (12). 913-916 (Pubitemid 20193675)
92. Tang YW, Johnson JE, Browning PJ, et al. Herpesvirus DNA is consistently detected in lungs of patients with idiopathic pulmonary fibrosis. J Clin Microbiol. 2003 ; 41 (6). 2633-2640 (Pubitemid 36712478)
93. Crawford SW, Hackman RC, Clark JG. Open lung biopsy diagnosis of diffuse pulmonary infiltrates after marrow transplantation. Chest. 1988 ; 94 (5). 949-953 (Pubitemid 18264634)
94. Myerson D, Hackman RC, Nelson JA, Ward DC, McDougall JK. Widespread presence of histologically occult cytomegalovirus. Hum Pathol. 1984 ; 15 (5). 430-439 (Pubitemid 15163003)
95. Renaud C, Campbell AP. Changing epidemiology of respiratory viral infections in hematopoietic cell transplant recipients and solid organ transplant recipients. Curr Opin Infect Dis. 2011 ; 24 (4). 333-343
96. Gasparetto EL, Escuissato DL, Inoue C, Marchiori E, Muller NL. Herpes simplex virus type 2 pneumonia after bone marrow transplantation: high-resolution CT findings in 3 patients. J Thorac Imaging. 2005 ; 20 (2). 71-73 (Pubitemid 40563428)
97. Han CS, Miller W, Haake R, Weisdorf D. Varicella zoster infection after bone marrow transplantation: incidence, risk factors and complications. Bone Marrow Transplant. 1994 ; 13 (3). 277-283 (Pubitemid 24065953)
98. Mariotte E, Schnell D, Scieux C, et al. Significance of herpesvirus 6 in BAL fluid of hematology patients with acute respiratory failure. Infection. 2011 ; 39 (3). 225-230
99. Dulery R, Salleron J, Dewilde A, et al. Early human herpesvirus type 6 reactivation after allogeneic stem cell transplantation: a large-scale clinical study. Biol Blood Marrow Transplant. 2012 ; 18 (7). 1080-1089
100. Cone RW. Human herpesvirus 6 as a possible cause of pneumonia. Semin Respir Infect. 1995 ; 10 (4). 254-258 (Pubitemid 26007457)
101. Cone RW, Hackman RC, Huang ML, et al. Human herpesvirus 6 in lung tissue from patients with pneumonitis after bone marrow transplantation. N Engl J Med. 1993 ; 329 (3). 156-161 (Pubitemid 23195735)
102. Ison MG. Adenovirus infections in transplant recipients. Clin Infect Dis. 2006 ; 43 (3). 331-339 (Pubitemid 44078906)
103. Panoskaltsis-Mortari A, Griese M, Madtes DK, et al. An official American thoracic society research statement: noninfectious lung injury after hematopoietic stem cell transplantation: idiopathic pneumonia syndrome. Am J Respir Crit Care Med. 2011 ; 183 (9). 1262-1279
104. Jinta M, Ohashi K, Ohta T, et al. Clinical features of allogeneic hematopoietic stem cell transplantation-associated organizing pneumonia. Bone Marrow Transplant. 2007 ; 40 (5). 465-472 (Pubitemid 47288227)
105. Yoshihara S, Yanik G, Cooke KR, Mineishi S. Bronchiolitis obliterans syndrome (BOS), bronchiolitis obliterans organizing pneumonia (BOOP), and other late-onset noninfectious pulmonary complications following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007 ; 13 (7). 749-759 (Pubitemid 46902446)
106. Barber NA, Ganti AK. Pulmonary toxicities from targeted therapies: a review. Target Oncol. 2011 ; 6 (4). 235-243
107. Patel AV, Hahn T, Bogner PN, et al. Fatal diffuse alveolar hemorrhage associated with sirolimus after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2010 ; 45 (8). 1363-1364
108. Machado CM, Dulley FL, Boas LS, et al. CMV pneumonia in allogeneic BMT recipients undergoing early treatment of pre-emptive ganciclovir therapy. Bone Marrow Transplant. 2000 ; 26 (4). 413-417 (Pubitemid 30649557)
109. Shepp DH, Dandliker PS, de Miranda P, et al. Activity of 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine in the treatment of cytomegalovirus pneumonia. Ann Intern Med. 1985 ; 103 (3). 368-373 (Pubitemid 15236570)
110. Biron KK. Antiviral drugs for cytomegalovirus diseases. Antiviral Res. 2006 ; 71 (2-3). 154-163 (Pubitemid 44223768)
111. Ljungman P, Deliliers GL, Platzbecker U, et al. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The infectious diseases working party of the european group for blood and marrow transplantation. Blood. 2001 ; 97 (2). 388-392 (Pubitemid 32060322)
112. Hakki M, Chou S. The biology of cytomegalovirus drug resistance. Curr Opin Infect Dis. 2011 ; 24 (6). 605-611
113. Biron KK, Harvey RJ, Chamberlain SC, et al. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob Agents Chemother. 2002 ; 46 (8). 2365-2372 (Pubitemid 34793437)
114. Avery RK, Marty FM, Strasfeld L, et al. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients. Transpl Infect Dis. 2010 ; 12 (6). 489-496
115. ClinicalTrials.gov Identifier NCT01611974. ClinicalTrials.gov..:
116. Price NB, Prichard MN. Progress in the development of new therapies for herpesvirus infections. Curr Opin Virol. 2011 ; 1 (6). 548-554
117. Goldner T, Hewlett G, Ettischer N, Ruebsamen-Schaeff H, Zimmermann H, Lischka P. The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol. 2011 ; 85 (20). 10884-10893
118. Kaul DR, Stoelben S, Cober E, et al. First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am J Transplant. 2011 ; 11 (5). 1079-1084
119. Waldman WJ, Knight DA, Lurain NS, et al. Novel mechanism of inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomide. Transplantation. 1999 ; 68 (6). 814-825 (Pubitemid 29468200)
120. Avery RK, Bolwell BJ, Yen-Lieberman B, et al. Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection. Bone Marrow Transplant. 2004 ; 34 (12). 1071-1075 (Pubitemid 40028840)
121. Battiwalla M, Paplham P, Almyroudis NG, et al. Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation. Transpl Infect Dis. 2007 ; 9 (1). 28-32
122. Snydman DR. Cytomegalovirus immunoglobulins in the prevention and treatment of cytomegalovirus disease. Rev Infect Dis. 1990 ; 12 (suppl 7). S839 - S848
123. Schmidt GM, Kovacs A, Zaia JA, et al. Ganciclovir/immunoglobulin combination therapy for the treatment of human cytomegalovirus-associated interstitial pneumonia in bone marrow allograft recipients. Transplantation. 1988 ; 46 (6). 905-907 (Pubitemid 19013240)
124. Reed EC, Bowden RA, Dandliker PS, Lilleby KE, Meyers JD. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med. 1988 ; 109 (10). 783-788 (Pubitemid 19046045)
125. Emanuel D, Cunningham I, Jules-Elysee K, et al. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med. 1988 ; 109 (10). 777-782 (Pubitemid 19046044)
126. Erard V, Guthrie K, Smith J, et al Cytomegalovirus pneumonia after hematopoietic cell transplantation: outcomes and factors associated with mortality.
127. Ljungman P, Engelhard D, Link H, et al. Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: experience of European bone marrow transplant group. Clin Infect Dis. 1992 ; 14 (4). 831-835
128. Ljungman P, Cordonnier C, Einsele H, et al. Use of intravenous immune globulin in addition to antiviral therapy in the treatment of CMV gastrointestinal disease in allogeneic bone marrow transplant patients: a report from the European group for blood and marrow transplantation (EBMT). Infectious diseases working party of the EBMT. Bone Marrow Transplant. 1998 ; 21 (5). 473-476 (Pubitemid 28107954)
129. Gerdemann U, Vera JF, Rooney CM, Leen AM.. Generation of multivirus-specific T cells to prevent/treat viral infections after allogeneic hematopoietic stem cell transplant. J. Vis. Exp. 2011 ; ( 51 ):
130. Hanley PJ, Cruz CR, Savoldo B, et al. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood. 2009 ; 114 (9). 1958-1967
131. Bao L, Dunham K, Stamer M, Mulieri KM, Lucas KG. Expansion of cytomegalovirus pp65 and IE-1 specific cytotoxic T lymphocytes for cytomegalovirus-specific immunotherapy following allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2008 ; 14 (10). 1156-1162
132. O'Reilly RJ, Doubrovina E, Trivedi D, Hasan A, Kollen W, Koehne G. Adoptive transfer of antigen-specific T-cells of donor type for immunotherapy of viral infections following allogeneic hematopoietic cell transplants. Immunol Res. 2007 ; 38 (1-3). 237-250 (Pubitemid 47574910)
133. Atkinson K, Downs K, Golenia M, et al. Prophylactic use of ganciclovir in allogeneic bone marrow transplantation: absence of clinical cytomegalovirus infection. Br J Haematol. 1991 ; 79 (1). 57-62
134. Winston DJ, Ho WG, Bartoni K, et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann Intern Med. 1993 ; 118 (3). 179-184 (Pubitemid 23034802)
135. Salzberger B, Bowden RA, Hackman RC, Davis C, Boeckh M. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome. Blood. 1997 ; 90 (6). 2502-2508 (Pubitemid 27392736)
136. Burns LJ, Miller W, Kandaswamy C, et al. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation. Bone Marrow Transplant. 2002 ; 30 (12). 945-951 (Pubitemid 36097485)
137. Li CR, Greenberg PD, Gilbert MJ, Goodrich JM, Riddell SR. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood. 1994 ; 83 (7). 1971-1979 (Pubitemid 24107924)
138. Boeckh M. Current antiviral strategies for controlling cytomegalovirus in hematopoietic stem cell transplant recipients: prevention and therapy. Transpl Infect Dis. 1999 ; 1 (3). 165-178
139. Ljungman P, de La Camara R, Milpied N, et al. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood. 2002 ; 99 (8). 3050-3056 (Pubitemid 34525398)
140. Winston DJ, Yeager AM, Chandrasekar PH, Snydman DR, Petersen FB, Territo MC. Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation. Clin Infect Dis. 2003 ; 36 (6). 749-758 (Pubitemid 36337979)
141. Winston DJ, Young JA, Pullarkat V, et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood. 2008 ; 111 (11). 5403-5410
142. Marty FM, Ljungman P, Papanicolaou GA, et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis. 2011 ; 11 (4). 284-292
143. Marty FM, Winston D, Rowley SD, Boeckh M, et al San Diego, CA: ASBMT Tandem Meeting ; February 2012:
144. Zimmermann H England: London ; April 2012:
145. Pollack M, Heugel J, Xie H, et al. An international comparison of current strategies to prevent herpesvirus and fungal infections in hematopoietic cell transplant recipients. Biol Blood Marrow Transplant. 2011 ; 17 (5). 664-673
146. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood. 1996 ; 88 (10). 4063-4071 (Pubitemid 26383133)
147. de Gast GC, Boland GJ, Vlieger AM, et al. Abortive human cytomegalovirus infection in patients after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1992 ; 9 (4). 221-225
148. Raanani P, Gafter-Gvili A, Paul M, Ben-Bassat I, Leibovici L, Shpilberg O. Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systematic review and meta-analysis. J Clin Oncol. 2009 ; 27 (5). 770-781
149. Kharfan-Dabaja MA, Boeckh M, Wilck MB, et al. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2012 ; 12 (4). 290-299
150. Griffiths PD, Stanton A, McCarrell E, et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet. 2011 ; 377 (9773). 1256-1263
151. La Rosa C, Longmate J, Lacey SF, et al. Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant. J Infect Dis. 2012 ; 205 (8). 1294-1304
152. Bacigalupo A, Tedone E, Sanna MA, et al. CMV infections following allogeneic BMT: risk factors, early treatment and correlation with transplant related mortality. Haematologica. 1992 ; 77 (6). 507-513 (Pubitemid 23028060)
153. Matthes-Martin S, Lion T, Aberle SW, et al. Pre-emptive treatment of CMV DNAemia in paediatric stem cell transplantation: the impact of recipient and donor CMV serostatus on the incidence of CMV disease and CMV-related mortality. Bone Marrow Transplant. 2003 ; 31 (9). 803-808 (Pubitemid 36656673)
154. Ljungman P, Aschan J, Lewensohn-Fuchs I, et al. Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients. Transplantation. 1998 ; 66 (10). 1330-1334 (Pubitemid 28551015)
155. Jaskula E, Dlubek D, Sedzimirska M, Duda D, Tarnowska A, Lange A. Reactivations of cytomegalovirus, human herpes virus 6, and Epstein-Barr virus differ with respect to risk factors and clinical outcome after hematopoietic stem cell transplantation. Transplant Proc. 2010 ; 42 (8). 3273-3276
156. Bachanova V, Brunstein CG, Burns LJ, et al. Fewer infections and lower infection-related mortality following non-myeloablative versus myeloablative conditioning for allotransplantation of patients with lymphoma. Bone Marrow Transplant. 2009 ; 43 (3). 237-244
157. Schetelig J, Oswald O, Steuer N, et al. Cytomegalovirus infections in allogeneic stem cell recipients after reduced-intensity or myeloablative conditioning assessed by quantitative PCR and pp65-antigenemia. Bone Marrow Transplant. 2003 ; 32 (7). 695-701 (Pubitemid 37258625)
158. Nichols WG, Corey L, Gooley T, et al. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. Blood. 2001 ; 97 (4). 867-874 (Pubitemid 32154267)
159. Lonnqvist B, Ringden O, Wahren B, Gahrton G, Lundgren G. Cytomegalovirus infection associated with and preceding chronic graft-versus-host disease. Transplantation. 1984 ; 38 (5). 465-468 (Pubitemid 15207398)
160. Remberger M, Aschan J, Barkholt L, Tollemar J, Ringden O. Treatment of severe acute graft-versus-host disease with anti-thymocyte globulin. Clin Transplant. 2001 ; 15 (3). 147-153 (Pubitemid 32487439)